retatrutide/cagrilintide blend EZP-3P/EZP-CG – 12.5mg/2.5mg – Research-Grade Compound retatrutide and cagrilintide blend +

Without regulatory oversight, third-party verification becomes the primary quality assurance mechanism

Community-derived weekly pattern (not from trials) Week Week 1 Amount 20 mg (20,000 mcg) If compared with 215.2 mg/mL liquid ~0.09 mL Week Week 2 Amount 24 mg (24,000 mcg) If compared with 215.2 mg/mL liquid ~0.11 mL Week Week 3 Amount 28 mg (28,000 mcg) If compared with 215.2 mg/mL liquid ~0.13 mL Week Week 4+ Amount 32 mg (32,000 mcg) If compared with 215.2 mg/mL liquid ~0.15 mL Community-derived, not trial-validated

Several days after the start of treatment, repeat testing showed improving bone marrow recovery, with an increase in reticulocyte count and normalization of lactate dehydrogenase

Red Fox Peptides supplies research peptides for laboratory research purposes only.